-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
A Powerful Partnership Ushers in a New Chapter: Lino Pharmaceutical, a Subsidiary of Keyuan Pharmaceutical, Signs a Strategic Cooperation Agreement with Hubei General Pharmaceutical Co., Ltd.
Publish Time:
2026-04-21
On April 21, Shandong Lino Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ), and Hubei General Pharmaceutical Co., Ltd. held a grand strategic cooperation signing ceremony. The two parties will join forces and complement each other’s strengths to deepen comprehensive cooperation in areas such as product distribution, industrial chain synergy, and medical terminal coverage, thereby focusing on serving the “Healthy China” strategy and jointly building a new pattern of high-quality development in the pharmaceutical industry.
On April 21, Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ) held a grand strategic cooperation signing ceremony with Hubei General Pharmaceutical Co., Ltd. through its wholly owned subsidiary, Shandong Linuo Pharmaceutical Co., Ltd. The two parties will join forces and complement each other’s strengths to deepen comprehensive cooperation in areas such as product distribution, industrial chain synergy, and medical terminal coverage, thereby focusing on supporting the “Healthy China” strategy and jointly building a new pattern of high-quality development in the pharmaceutical industry.
Li Hongfu, Chairman of Keyuan Pharmaceutical and Linuo Pharmaceutical, Yu Shijun, Secretary of the Party Branch, Director, and General Manager of Hubei General Pharmaceutical, along with relevant officials from both sides, attended and witnessed the signing ceremony.
Hubei General Pharmaceutical is a core regional platform under China General Technology Group and China National Pharmaceutical Group, deeply engaged in the pharmaceutical and healthcare industry. It boasts a well-established distribution network, extensive market coverage, and strong industry credibility. Linuo Pharmaceutical is a wholly owned subsidiary of Keyuan Pharmaceutical, a leading player in China’s specialized chemical API segment. The company focuses on pharmaceutical R&D, manufacturing, and sales, with a robust product portfolio spanning cardiovascular, psychotropic and neurological, diabetes, anti-inflammatory and antimicrobial, and respiratory therapeutic areas. It has established a diversified product lineup that covers multiple dosage forms, including solid dosage forms, injectables, oral solutions, drops, liniments, pastes, and sprays.
The two parties’ respective resource advantages are highly complementary, and this strategic cooperation will usher in a new chapter of synergistic development across the pharmaceutical industry—encompassing manufacturing, distribution, and trade. Under the agreement, the two sides will focus on deepening collaboration in three key areas: first, expanding product distribution networks and leveraging their respective platform strengths to achieve nationwide coverage; second, strengthening supply-chain collaboration to streamline the entire value chain and share high-quality resources; and third, intensifying engagement at the clinical front line to ensure that premium, high-quality medicines reach end-users directly and benefit the general public.
In his address, Chairman Li Hongfu stated that Hubei General Pharmaceutical is a strong, reliable, and outstanding partner. Lino Pharmaceutical will deepen cooperation with the utmost sincerity, superior service, and stable supply, leveraging Hubei General’s well-established distribution network to ensure efficient access of high-quality pharmaceutical products to end-users, and jointly set a benchmark for collaboration between central and local pharmaceutical enterprises.
A powerful alliance ushers in a new chapter, with united hearts and minds building the dream of health. The signing of this strategic cooperation agreement marks the entry of our collaboration into a new phase of substantive implementation. Moving forward, Linuo Pharmaceutical and Hubei General Pharmaceutical will uphold the principles of integrity, mutual benefit, pragmatism, and efficiency, establish a long-term cooperative mechanism, and steadily advance the realization and impact of all collaborative initiatives. Together, we will leverage stronger synergy, superior services, and higher quality to continuously drive the advancement of China’s pharmaceutical and healthcare sector.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline